Ameriprise Financial Inc. Trims Stake in Regeneron Pharmaceuticals, Inc. (REGN)

Ameriprise Financial Inc. decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 217,208 shares of the biopharmaceutical company’s stock after selling 60,850 shares during the period. Ameriprise Financial Inc. owned approximately 0.21% of Regeneron Pharmaceuticals worth $106,908,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the company. Alpha Windward LLC boosted its position in shares of Regeneron Pharmaceuticals by 0.3% during the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 1 shares in the last quarter. Concert Wealth Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 0.4% during the 1st quarter. Concert Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 3 shares in the last quarter. Cleararc Capital Inc. boosted its position in shares of Regeneron Pharmaceuticals by 0.3% during the 1st quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock valued at $717,000 after purchasing an additional 5 shares in the last quarter. Regentatlantic Capital LLC boosted its position in shares of Regeneron Pharmaceuticals by 0.9% during the 2nd quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock valued at $264,000 after purchasing an additional 5 shares in the last quarter. Finally, Capital Planning Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 2.1% during the 2nd quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 12 shares in the last quarter. Institutional investors own 67.96% of the company’s stock.

In related news, EVP Neil Stahl sold 8,306 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $532.55, for a total value of $4,423,360.30. Following the completion of the transaction, the executive vice president now directly owns 43,950 shares in the company, valued at approximately $23,405,572.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael S. Aberman sold 2,269 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $532.42, for a total value of $1,208,060.98. Following the completion of the transaction, the senior vice president now owns 9,193 shares of the company’s stock, valued at $4,894,537.06. The disclosure for this sale can be found here. Insiders have sold a total of 99,543 shares of company stock valued at $47,831,369 over the last 90 days. Corporate insiders own 10.40% of the company’s stock.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 433.45 on Friday. The firm’s 50-day moving average is $472.80 and its 200-day moving average is $445.37. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The stock has a market capitalization of $45.96 billion, a price-to-earnings ratio of 43.48 and a beta of 1.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.82 EPS. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.90 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on the stock. Leerink Swann restated an “outperform” rating and set a $573.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 22nd. Raymond James Financial, Inc. restated an “outperform” rating and set a $547.00 price objective (up previously from $475.00) on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 22nd. Bank of America Corporation restated a “buy” rating and set a $593.00 price objective (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. BMO Capital Markets restated a “market perform” rating and set a $484.00 price objective (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Finally, Sanford C. Bernstein lowered shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their price objective for the company from $410.00 to $480.00 in a research report on Monday, June 26th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $491.43.

WARNING: “Ameriprise Financial Inc. Trims Stake in Regeneron Pharmaceuticals, Inc. (REGN)” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/17/ameriprise-financial-inc-trims-stake-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply